Want to see ELOX full AI Analyst Report?
ELOX Stock Chart & Stats
$14.19
$0.00(0.00%)
At close: 4:00 PM EST
$14.19
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.23 - $23.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)43.89K
Market Cap
$63.57M
Enterprise Value$13.98
Total Cash (Recent Filing)$61.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-2301.39
Next Earnings
Nov 11, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding4,036,459
10 Day Avg. Volume31,948
30 Day Avg. Volume43,888
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.33Price Target Upside184.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Substantial Reduction In LossesThe sharp reduction in annual net losses indicates meaningful progress in controlling the company’s cost base and development spending. Although Eloxx remains unprofitable, a smaller loss profile can extend financial runway and improve the potential economics of future clinical execution.
Meaningful Debt ReductionDebt reduction materially lowers fixed financial obligations and interest-related pressure compared with prior years. This deleveraging is a durable balance-sheet improvement that may preserve more resources for research, clinical development, and regulatory preparation, even though equity remains negative.
Focused Rare-disease PlatformEloxx’s focus on genetically defined rare diseases and nonsense-mutation read-through creates a specialized development platform rather than a broad, undifferentiated drug pipeline. Concentrated expertise in this mechanism could support repeat applications across multiple high-need conditions.
Bears Say
No Durable Commercial RevenueThe absence of consistent commercial revenue leaves Eloxx without a dependable operating funding base and makes financial results highly unpredictable. Until a program generates recurring sales or partnership income, the company’s ability to support development depends on uncertain future financing or milestones.
Negative Shareholder EquityNegative equity reflects accumulated losses and leaves the company with limited balance-sheet protection against further setbacks. This weak financial cushion can constrain strategic flexibility, reduce resilience during clinical or regulatory delays, and increase dependence on external capital to continue operations.
Persistent Operating Cash BurnEloxx continues to consume cash in its operations, so current activities are not self-funding despite the improvement from approximately -$35.0M in 2021. Ongoing burn means additional financing may remain necessary to sustain research and clinical programs over the coming quarters.
Eloxx Pharmaceuticals News
ELOX FAQ
What was Eloxx Pharmaceuticals’s price range in the past 12 months?
Eloxx Pharmaceuticals lowest stock price was $0.23 and its highest was $23.40 in the past 12 months.
What is Eloxx Pharmaceuticals’s market cap?
Eloxx Pharmaceuticals’s market cap is $63.57M.
When is Eloxx Pharmaceuticals’s upcoming earnings report date?
Eloxx Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 56 days.
How were Eloxx Pharmaceuticals’s earnings last quarter?
Eloxx Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.66 earnings per share for the quarter.
Is Eloxx Pharmaceuticals overvalued?
According to Wall Street analysts Eloxx Pharmaceuticals’s price is currently Undervalued.
Does Eloxx Pharmaceuticals pay dividends?
Eloxx Pharmaceuticals does not currently pay dividends.
What is Eloxx Pharmaceuticals’s EPS estimate?
Eloxx Pharmaceuticals’s EPS estimate is -0.65.
How many shares outstanding does Eloxx Pharmaceuticals have?
Eloxx Pharmaceuticals has 4,036,459 shares outstanding.
What happened to Eloxx Pharmaceuticals’s price movement after its last earnings report?
Eloxx Pharmaceuticals reported an EPS of -$0.66 in its last earnings report. Following the earnings report the stock price went down -4.771%.
Which hedge fund is a major shareholder of Eloxx Pharmaceuticals?
Currently, no hedge funds are holding shares in ELOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eloxx Pharmaceuticals Stock Smart Score
Company Description
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
ELOX Stock 12 Month Forecast
Average Price Target
$40.33
▲(184.24% Upside)
Technical Analysis
AIM ImmunoTech
―
Biodexa Pharmaceuticals
―
―
Dermata Therapeutics
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
51.60% Insiders
<0.01% Other Institutional Investors
48.40% Public Companies and
Individual Investors